Might prostate cancer be a sleep deprivation-related disorder?

According to a report on a presentation given yesterday at an ongoing meeting in Washington, DC, “Adequate sleep isn’t a luxury; it’s essential. And for men, it might even mean the difference between life and death”. … READ MORE …

Yes guys … exercise is good for men on ADT!

It has long been understood that taking regular exercise can be helpful in management of risk for fatigue among men being treated with androgen deprivation therapy (ADT) for prostate cancer — whatever the stage of prostate cancer that the patient is being treated for. … READ MORE …

Real care beyond medical treatment, and impact on quality of life

A small, recent pilot study in Geneva, Switzerland, has shown that radiation therapy (RT) + androgen deprivation therapy (ADT) can be given safely to frail patients with non-metastatic, locally advanced or aggressive, intermediate prostate cancer, if and when a multidisciplinary care program is implemented to help such frail patients to limit risk for and manage predictable side effects. … READ MORE …

Nadir PSA predicts survival after radiation and androgen deprivation for unfavorable risk patients

The following commentary addresses the article on risk for recurrent prostate cancer that we had mentioned briefly yesterday.

If a treatment isn’t working, we want to know as quickly as possible so we can try a salvage therapy while it can still make a difference. … READ MORE …

ADT + EDT in the treatment of advanced prostate cancer?

An article published on line last year in Anticancer Research has just come to our attention. It puts forward the relatively simple proposal that by combining androgen deprivation therapy (ADT) with estrogen deprivation therapy (EDT) we might be able to significantly impact the risk for development of castration-resistant prostate cancer (CRPC). … READ MORE …

IADT — pro and con; a follow-up

The other day we mentioned two articles in a recent issue of JAMA Oncology that dealt with the role of intermittent androgen deprivation therapy (IADT) in the management of progressive prostate cancer today. We have now had the good fortune to be able to read both of the two articles in full, thanks to a kind correspondent. … READ MORE …

Starting the new year with two of the usual controversies

Strictly speaking, JAMA Oncology actually ended the old year (in its issue on December 29, 2016), rather than beginning the new one, with two articles, a letter to the editor, and an editorial that deal with two of the more controversial issues that affect the way we think about the management of prostate cancer. … READ MORE …